NCT05650723 2026-02-25
Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
Weill Medical College of Cornell University
Phase 2 Active not recruiting
Weill Medical College of Cornell University
BeOne Medicines
M.D. Anderson Cancer Center
BeOne Medicines
City of Hope Medical Center
German CLL Study Group
Ruijin Hospital
Sun Yat-sen University
Northwestern University
Fudan University